Champions OncologyCSBR -0.98%64 Median PS Value is $9.58 as of Jun. 25, 2026, which is 1288% above its 10-year median of 0.69. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 277 Biotechnology companies, Champions Oncology ranks worse than 51.99% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Champions Oncology's Median PS Value or its related term are showing as below:
CSBR'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32 Med: 0.69 Max: 1.59
Current: 0.63
During the past 13 years, the highest Price to Median PS Value of Champions Oncology was 1.59. The lowest was 0.32. And the median was 0.69.
CSBR's Price-to-Median-PS-Value is ranked worse than 51.99% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs CSBR: 0.63
Champions Oncology (NAS:CSBR) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Champions Oncology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
6.08
/
9.58
=
0.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Median PS Value Related Terms
Champions Oncology Median PS Value Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Median PS Value Comparison
For the Biotechnology subindustry, Champions Oncology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.3429.
Champions Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.089.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a Median PS Value of $9.58 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Champions Oncology and its competitors. This is 1288% above median its historical median of 0.69. Over the past decade, Champions Oncology's Median PS Value has ranged from 0.32 to 1.59. According to the industry distribution chart, Champions Oncology ranks #144 out of 277 companies in the Biotechnology industry, placing it in the top 52%.
Is Champions Oncology's Median PS Value too high?
Champions Oncology's current Median PS Value of $9.58 is 1288% above median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 1.59. The Biotechnology industry median Median PS Value is 0.63. Champions Oncology's value of $9.58 is 1420.6% above this industry median. Based on the distribution chart, Champions Oncology ranks #144 out of 277 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Median PS Value compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #144 out of 277 companies for Median PS Value. This places Champions Oncology in the lower half of its industry. The industry median Median PS Value is 0.63. Champions Oncology's value of $9.58 is 1420.6% above this benchmark. Historically, Champions Oncology's own Median PS Value has ranged from 0.32 to 1.59 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.63, Champions Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Median PS Value of $9.58 is 1420.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Median PS Value is $9.58, which is 1288% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.08 — trading 8.2% below its estimated fair value. The current Median PS Value is $9.58, which is 1288% above median its 10-year median of 0.69 and 1420.6% above the Biotechnology industry median of 0.63. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Median PS Value is $9.58 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.08 is trading 8.2% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Median PS Value: $9.58 (1288% above median its 10-year median of 0.69)
GF Value™: $6.62 vs. price of $6.08 (8.2% below fair value)
Industry Position: 1420.6% above the Biotechnology median (#144 of 277)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
